Pharm-Olam International geselecteerd voor uitbesteed tweedefaseonderzoek naar lymfoom
HOUSTON–(BUSINESS WIRE)– Pharm-Olam International Ltd., een multinationaal bedrijf in uitbesteed onderzoek voor biofarmacie en medische apparatuur, kondigt met blijdschap aan dat het door Infinity Pharmaceuticals, Inc. is geselecteerd voor de het onderzoek FRESCO, een medische fase 2-proef met een experimenteel medicijn tegen een teruggekeerd of hardnekkig folliculair lymfoom.
“Het verheugt ons enorm dat we onze samenwerking met Infinity kunnen voortzetten”, zei Sanjiv Suri, ceo van Pharm-Olam in de Verenigde Staten. “Het team van Infinity eiste een snel, flexibel systeem voor de tijdige kwaliteitslevering. Het zijn de merites van onze projectgroepen dat Infinity heeft besloten verder te gaan met Pharm-Olam bij toekomstige klinische plannen.”
Pharm-Olam International Announces That It Has Been Appointed as Contract Research Organization for Global Phase 2 Lymphoma Study |
|||||
|
HOUSTON–(BUSINESS WIRE)– Pharm-Olam International Ltd., a multi-national, full-service Clinical Research Solutions Organization to the biopharmaceutical and medical device industries, is pleased to announce that is has been selected as the Contract Research Organization for Infinity Pharmaceuticals, Inc. for the conduct of Infinity’s FRESCO study, a Phase II clinical trial of an investigational medicine for the treatment of relapsed/refractory follicular lymphoma. “We are extremely pleased to continue our collaboration with Infinity,” said Sanjiv Suri, Pharm-Olam’s Chief Executive Officer (USA). Suri added, “The Infinity team required a fast, flexible solution to provide a timely quality deliverable. It is a credit to our project teams that Infinity has decided to continue with Pharm-Olam as a part of its future clinical plans.” Infinity previously partnered with Pharm-Olam for Clinical, Project Management, Medical Monitoring, Data Management, and Regulatory Services for DYNAMO™, a Phase II study for patients with refractory indolent non-Hodgkin’s lymphoma (iNHL). Both companies share a commitment to advancing new investigational medicines for people with difficult-to-treat diseases. Pharm-Olam provided the speed and flexibility required for Infinity’s DYNAMO study and rapidly identified and engaged with its network of specialist sites and organizations to meet enrollment goals. With extensive study and functional outsourcing experience, Pharm-Olam’s established competencies, global staff network and flat organizational structure proved a strong match for Infinity. “In working with Pharm-Olam on the DYNAMO study, Pharm-Olam assigned Infinity a team of very capable individuals who complement one another in their unique strengths. We are pleased that they are now also supporting our Phase II FRESCO study,” stated Ross Pettit, Infinity’s Senior Vice President, Development Operations. “Pharm-Olam not only has deep expertise but also puts exceptional energy and enthusiasm into the work that they do. They have played a key role in helping Infinity to execute and advance its lead clinical program, and we are pleased to continue our collaboration.” For more information about Pharm-Olam and its global Phase I-IV clinical research solutions, contact info@pharm-olam.com. About Pharm-Olam International Group Pharm-Olam International is a multi-national Contract Research Organization (CRO) offering a wide range of comprehensive, clinical research services to the pharmaceutical, biotechnology and medical device industries. From Phase I to Phase IV, Pharm-Olam focuses on delivering the highest quality data, achieving targeted enrollment and meeting projected timelines. For further information about Pharm-Olam, please visit www.pharm-olam.com. View source version on businesswire.com: http://www.businesswire.com/news/home/20160224005341/en/ Contacts Pharm-Olam International |
|||||